Antiretroviral therapy in developing countries: pharmacologic considerations

dc.contributor.author Lamorde, Mohammed
dc.contributor.author Byakika-Kibwika, Pauline
dc.contributor.author Merry, Concepta
dc.date.accessioned 2011-12-29T12:21:56Z
dc.date.available 2011-12-29T12:21:56Z
dc.date.issued 2008
dc.description.abstract Purpose of review This article reviews recent studies in the field of clinical pharmacology of antiretroviral drugs and highlights the relevance of the findings to clinical practice in developing countries. Recent findings Differences in antiretroviral pharmacokinetics are associated with polymorphisms of genes encoding drug metabolizing enzymes. Inadequate concentrations of antiretrovirals in children are common. A study in African children found subtherapeutic concentrations in 40% of patients receiving efavirenz at recommended doses. Summary Recent findings on the pharmacokinetics of antiretroviral agents relevant to clinical practice in developing countries are reviewed. Widespread poverty impacts negatively on HIV/AIDS treatment and prevention efforts. Improved access to treatment, social and economic support and pharmacology research in target populations are needed. en_US
dc.identifier.citation Lamorde M,Byakika-Kibwika P,Merry C. Antiretroviral therapy in developing countries: pharmacologic considerations Vol 3 en_US
dc.identifier.issn 1746-630X
dc.identifier.uri http://hdl.handle.net/10570/273
dc.language.iso en en_US
dc.publisher Lippincott Williams & Wilkins en_US
dc.subject Anti-HIV agents en_US
dc.subject Developing countries en_US
dc.subject Drug interactions en_US
dc.subject Pharmacokinetics en_US
dc.subject Toxicity en_US
dc.title Antiretroviral therapy in developing countries: pharmacologic considerations en_US
dc.type Journal article, peer reviewed en_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: